Too Much of a Good Thing? How Overdoing a Key Brain Modification Leads to Neuron Problems
"New research reveals how excessive glutamylation, a crucial modification in brain cells, can trigger neurodegeneration, offering potential targets for future therapies."
Microtubules, the structural filaments within our cells, are essential for maintaining cell architecture, including shape, polarity, and the transport of organelles. To support this wide array of functions, microtubules adapt their structure and dynamics based on cell type, developmental stage, and even the specific subset of microtubules within a single cell.
This specialization relies on the use of different tubulin isotypes, microtubule-associated proteins (MAPs), and post-translational modifications of tubulin. A key modification is polyglutamylation, where polyglutamate tails are added to the C-termini of α-tubulin or β-tubulin. This process involves adding a glutamic acid residue to a gene-encoded glutamate, and the resulting polypeptide chain can be elongated by further glutamate additions.
Two recent studies have shed light on the importance of this modification, demonstrating that excessive accumulation of polyglutamylation leads to neurodegeneration in both mice and humans. This groundbreaking research points to defects in axonal microtubule-based transport as a likely cause.
Measuring Brain Health’s Burden
The Institute for Health Metrics and Evaluation’s Brain Health Atlas is designed to quantify the present burden, future trends, and economic impact of brain health conditions, using data to inform policy change. Its interactive data site presents a timeline intended to show how brain health may change over time. The listed sources describe broad coverage of topics such as dementia, sleep, nutrition, exercise, stress, and screen time, but the supplied material gives no specific prevalence figures or other statistics to report.
Beyond Single-Cause Explanations
The sources describe Alzheimer’s and Parkinson’s as growing burdens amid an aging global population, while effective preventive or disease-modifying therapies remain limited. A 2025 brain-health framework argues that views dominated by the amyloid-beta hypothesis oversimplify neurodegeneration and proposes examining the brain as a complex system through a multi-scale, multi-entity approach. It advocates more comprehensive, multifactorial research and clinical practice to advance treatment of disorders such as Alzheimer’s disease.
The Delicate Balance: Why Too Much Glutamylation is Harmful
Glutamylation is a reversible process, with glutamate residues being removed by members of the cytosolic carboxypeptidase (CCP) family. While tubulin is the primary target, other substrates are also known. Polyglutamylation affects the structure and increases the negative charge of tubulin tails, which are crucial for interactions with various MAPs. This modification is found on spindle and midbody microtubules during cell division and is enriched on centrioles, cilia, and neuronal microtubules.
- CCP1's Multifaceted Role: CCP1 removes polyglutamate chains and gene-encoded C-terminal acidic residues from proteins, including tubulin.
- Unanswered Questions: Whether sensitivity to CCP1 levels is a general property of neurons, and the underlying mechanisms, remained unclear.
Tubulin Deglutamylation and Neuron Loss
Research on childhood-onset neurodegeneration with cerebellar atrophy (CONDCA; OMIM 618276) links the rare disease to AGTPBP1-related CCP1 dysfunction affecting microtubules in the cerebellum, spinal motor neurons, and peripheral nerves. In the pcd model, deglutamase mRNA and protein were virtually absent before Purkinje neurons degenerated, while glutaminase mRNA and protein remained normal. A review notes that microtubule-related defects in axonal transport have been proposed as a mechanism in neurodegeneration.
Degeneration Is Not Inevitable
A 2026 resilience model argues that neurodegeneration is not an inevitable consequence of aging, but may arise when cumulative biological stress exceeds the brain’s intrinsic protective capacity. The model frames disease as a failure of integrated resilience systems that maintain neural homeostasis. Separately, a review describes neurodegenerative disease pathogenesis as multifactorial and complex, with neuronal loss varying by disease and degeneration typically progressing from subcortical toward cortical regions.
A Broader Brain-Health Paradigm
A 2015 article argues that a new “brain health” paradigm is essential to understanding neurodegenerative disorders such as Alzheimer’s disease and addressing the relative standstill in therapeutics research it describes over the preceding decade. A 2025 editorial likewise presents brain health as a pressing challenge as the global population ages and Alzheimer’s and Parkinson’s impose increasing burdens, with effective preventive or disease-modifying therapies still limited. The supplied sources offer these broad perspectives but do not provide comparative measurements of particular interventions.
From Mice to Humans: Implications for Neurodegenerative Disease
This research leads to several important conclusions. First, the toxicity of losing CCP1 activity is due to increased polyglutamylation, not the removal of gene-encoded glutamates. Second, increased, but not decreased, polyglutamylation compromises neuronal survival. Third, hyperglutamylation causes neuronal death in a cell-autonomous manner.
Understanding Mechanisms for Healthy Aging
A 2025 Frontiers editorial emphasizes that uncovering the molecular mechanisms underlying aging and neurodegeneration is essential for advancing strategies to promote healthy aging. The source frames this as an active and evolving research landscape. It does not specify a particular mechanism or intervention in the supplied description.
New Brain Atlases and Therapeutic Directions
A 2022 editorial anticipates that research on neurodegeneration will expand knowledge of biological bases, clinical research, and emerging challenges, while offering insights into therapeutic approaches for neurological disorders. At Stanford’s Knight Initiative Fall Symposium, reported in November 2025, researchers presented work building new molecular atlases of the brain alongside updates on neurodegenerative disease and possible responses. Together, these sources point to ongoing research directions rather than established clinical outcomes.
Collaboration and Tissue-Based Discovery
The Cleveland Brain Health Initiative’s Neurodegeneration Study Group brings together investigators studying Alzheimer’s disease, Parkinson’s disease, dementia, and other neurodegenerative diseases. A 2025 article proposes “transformative neuropathology,” using dynamic, technology-integrated approaches to accelerate tissue-based discoveries. Its recommendations include strengthening brain banks, improving tissue quality, harmonizing digital pathology, and applying machine learning through cross-disciplinary collaboration.
Intriguingly, studies have revealed that the loss of tubulin deglutamylase CCP1 causes infantile-onset neurodegeneration in humans, marked by abnormalities in the cerebellum, spinal motor neurons, and peripheral nerves – mirroring the pathology observed in the pcd mouse.
These findings strongly suggest that an impaired balance in microtubule polyglutamylation has a significant impact on neuronal survival in humans, opening avenues for therapies modulating the activity of enzymes controlling this modification to inhibit neurodegeneration.